Anzeige
Mehr »
Freitag, 24.04.2026 - Börsentäglich über 12.000 News
Während Miner kämpfen, entsteht in Finnland der vielleicht billigste Bitcoin Europas
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Alliance News

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
MiUPDATE: BHP quarterly copper production falls, iron ore output gains
MiHaleon drops supplier after AFP deforestation investigation
MiLondon hosts military talks on France and UK's Hormuz mission
DiTRADING UPDATES: Vaalco says remainder of 2026 to be "very profitable"
DiUK agrees ban on cigarette sales for people born after 2008
DiEARNINGS AND TRADING: Mpac swings to loss; Gear4music sales rise 30%
DiSaba eyes investment manager role at EWI under replacement board
DiSaba requisitions meeting to replace IEM board following tender offer
DiTRADING UPDATES: capAI hails outlook; Intercede wins new orders
DiJupiter Fund hails "positive momentum" but warns war hits sentiment
DiLONDON MARKET CLOSE: FTSE 100's early gains fade as war deadline looms
DiIreland warns of stagflation risk as Mideast war bites
DiMercantile Ports & Logistics stock sinks amid debt dispute
DiAEW UK REIT backs away from making Alternative Income REIT bid
DiIN BRIEF: Sika eyes Central Asia growth with new Kyrgyzstan business
DiCapital mining revenue multiplies, investments fall in first quarter
DiEARNINGS AND TRADING: Accsys sees results in line; CAB Payments grows
DiLONDON MARKET MIDDAY: Stocks move higher as ceasefire deadline looms
DiEXECUTIVE CHANGES: Ibstock poaches CFO from Mpac; Windar hires CEO
DiXPS Pensions reports continued strong trading with broad-based growth
DiWINNERS & LOSERS: Nichols trades in line; Crest Nicholson slumps
DiIN BRIEF: Tern makes open offer of shares to raise GBP640,000
DiIntegraFin Holdings backs guidance after "impressive" second quarter
DiWINNERS & LOSERS: Ocado rises again; THG's first quarter impresses
DiAstraZeneca says Ultomiris meets primary endpoint in phase III trial